Building a Urologic Registry Using Microbiome Analysis for Personalized Care in Korean Patients With Prostate, Kidney, Bladder, and Ureter Cancers

What this Trial Is About

Genitourinary cancers such as prostate cancer, renal cell cancer, bladder cancer, and ureter cancer have been increasing in the Korean population due to aging and lifestyle changes. Researchers are studying how the microbiome in tissues, blood plasma, stool, and urine may help detect these cancers, monitor disease progression, and evaluate treatment responses. This observational study aims to build a large database of the microbiome related to urological malignancies in Korean patients. The study collects samples from patients who have been diagnosed with urological cancers and have undergone surgeries such as prostatectomy, nephrectomy, cystectomy, or ureterectomy. Samples include tissue, plasma, stool, and urine collected within two weeks after surgery. The study will analyze the composition of bacteria in these samples and correlate them with the presence of cancer and tumor response over up to 10 years. Participants provide permission to use their biological samples and medical information for this research. Researchers will assess bacterial composition and its correlation with cancer prevalence shortly after surgery and track tumor response using standardized criteria for up to ten years. The study involves long-term monitoring and data collection to support personalized medicine approaches for urological cancers in Korea.

Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome